NASDAQ:MNOV - MediciNova, Inc.
$7.63
 $0.81
+11.88%
2:35PM EDT
2019-02-15
Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MNOV     avg for
industry  
  avg for
sector  
42 stocks weight:  8. 62   0. 00   0. 00  
42 stocks rank:  3. 95 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  

quick ratio:  34. 60   5. 37   1. 81  
current ratio:  34. 81   5. 69   2. 19  

target price low:  18. 00   88. 97   117. 82  
target price avg:  20. 00   115. 19   141. 96  
target price high:  7. 00   143. 40   163. 16  
1-yr high:  13. 91   124. 30   142. 77  
last close:  6. 82   101. 85   127. 84  
50-day avg:  8. 81   98. 27   122. 46  
200-day avg:  9. 73   99. 72   122. 70  
1-yr low:  6. 82   78. 19   100. 16  
volume:  138. 34 K 2. 38 M 4. 64 M
50-day avg volume:  70. 28 K 3. 31 M 4. 94 M
200-day avg volume:  85. 98 K 3. 23 M 4. 28 M

1-day return:  -16. 63 % 0. 22 % 0. 48 %
this week return:  -19. 10 % 1. 77 % 2. 01 %
12-wk return:  -28. 74 % 6. 56 % 3. 33 %
52-wk return:  -24. 47 % -2. 23 % 14. 35 %

enterprise value (EV):  280. 15 M 55. 17 B 104. 51 B
market cap:  285. 63 M 49. 01 B 96. 46 B
EBITDA:  -18. 48 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -15. 16   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -16. 07 M 2. 37 B 3. 58 B

shares outstanding:  41. 88 M 607. 99 M 1. 22 B
shares:  37. 78 M 605. 53 M 1. 15 B
shares short:  3. 14 M 11. 62 M 12. 55 M
shares short prior month:  3. 10 M 11. 95 M 13. 44 M
short ratio:  55. 64   4. 82   3. 10  
short % of float:  8. 10 % 6. 19 % 2. 82 %
total cash/share:  1. 49   12. 02   11. 46  
total cash:  62. 44 M 7. 41 B 7. 37 B
free cash flow:  -2. 24 M 95. 99 M 2. 04 B
operating cash flow:  -8. 52 M 164. 74 M 3. 04 B

book value:  1. 76   14. 43   28. 26  
price/book:  3. 88   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  18. 88 % --- ---
1-yr mean volatility:  -0. 06 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 41   3. 03   4. 09  
forward EPS:  -0. 77   4. 33   6. 99  
P/E:  -16. 84   6. 11   26. 91  
forward P/E:  -8. 86   8. 38   10. 48  
PE/G:  3. 31   0. 37   5. 61  
growth:  -5. 08 % 683. 72 % 104. 79 %
earnings high:  -0. 00   1. 27   1. 66  
earnings avg:  -0. 00   1. 01   1. 53  
earnings low:  -0. 00   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -19. 70 % -3. 27 % 3. 81 %
return on equity:  -29. 68 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 21   1. 21   0. 93  
sharpe (1yr):  -0. 21   0. 06   0. 98  

held % insiders:  11. 59 % 6. 46 % 3. 21 %
held % institutions:  26. 90 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : MNOV
.    + 2.207 =         2.207 :: INITIAL WEIGHT
.  + 193.881 =       196.087 :: inverse volume-to-price addition
.  + 467.461 =       663.548 :: spline projection addition
.  - 152.504 =       511.044 :: poor performance penalty
.    x 0.825 =       421.705 :: one-year gains+dividend factor
.    x 0.756 =       318.686 :: 13 weeks' performance factor
.    x 1.492 =       475.635 :: industry recommendation factor
.    x 0.998 =       474.698 :: return on assets factor
.    x 0.997 =       473.289 :: return on equity factor
.    x 5.185 =      2454.211 :: current ratio factor
.    x 1.015 =      2490.461 :: quick ratio factor
.    x 1.009 =      2512.741 :: short ratio factor
.    x 2.039 =      5123.073 :: price-to-book factor
.    x 2.058 =     10541.941 :: P/E weight
.    x 0.741 =       7814.38 :: PE/G factor
.    x 1.754 =     13708.235 :: beta factor
.    x 0.213 =      2920.718 :: sharpe factor
.    x 2.488 =      7266.413 :: target low factor
.    x 1.463 =     10633.578 :: target mean factor
.    x 1.016 =     10807.677 :: target high factor
.    x 1.066 =     11516.799 :: industry 12-weeks return
.    x 0.924 =     10643.731 :: "drift" penalty 4 days ago
.    x 0.798 =      8491.982 :: "drift" penalty 5 days ago
.    x 0.965 =      8190.992 :: overall "drift" factor
.    x 0.811 =      6644.162 :: largest single-day jump factor
.    x 0.097 =       641.328 :: low price factor
.      x 1.0 =       641.371 :: factor hist industry gain for week 06
.   cubeRoot =         8.624 :: reduced for readability
.                      8.624 :: FINAL WEIGHT for NASDAQ:MNOV


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org